Related Experiment Video
Updated: Mar 2, 2026
Prion Safety Laboratory Swipe Test
Published on: February 14, 2025
Inhibition of Prion Propagation by 3,4-Dimethoxycinnamic Acid
Ivan Zanyatkin1, Yulia Stroylova1,2, Sofia Tishina1
1Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Leninskye gory, 1/40, 119234, Russia.
Abstract:
Neurodegenerative diseases are associated with accumulation of amyloid-type protein misfolding products. Prion protein (PrP) is known for its ability to aggregate into soluble oligomers that in turn associate into amyloid fibrils. Preventing the formation of these infective and neurotoxic entities represents a viable strategy to control prion diseases. Numerous attempts to find dietary compounds with anti-prion properties have been made; however, the most promising agent found so far was curcumin, which is poorly soluble and merely bioavailable. In the present work, we identify 3,4-dimethoxycinnamic acid (DMCA) which is a bioavailable coffee component as a perspective anti-prion compound. 3,4-Dimethoxycinnamic acid was found to bind potently to prion protein with a Kd of 405 nM. An in vitro study of DMCA effect on PrP oligomerization and fibrillization was undertaken using isothermal titration calorimetry (ITC), dynamic light scattering (DLS) and circular dichroism (CD) methodologies. We demonstrated that DMCA affects PrP oligomer formation reducing the oligomer content by 30-40%, and enhancing SH-SY5Y cell viability treated with prion oligomers. Molecular docking studies allowed to suggest a site where DMCA is able to bind stabilizing PrP tertiary structure. We suggest that DMCA is a perspective dietary compound for prophylaxis of neurodegenerative diseases that needs further research. Copyright © 2017 John Wiley & Sons, Ltd.
Insights
3,4-dimethoxycinnamic acid (DMCA), a coffee component, shows promise in preventing prion protein aggregation. This dietary compound may offer a new strategy for managing neurodegenerative diseases by stabilizing prion protein structures.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Neurodegenerative diseases are linked to misfolded amyloid proteins.
- Prion protein (PrP) aggregation into amyloid fibrils is implicated in prion diseases.
- Effective anti-prion compounds are needed, but existing options like curcumin have poor bioavailability.
Purpose of the Study:
- To identify dietary compounds with anti-prion properties.
- To investigate the potential of 3,4-dimethoxycinnamic acid (DMCA) as an anti-prion agent.
Main Methods:
- In vitro studies using isothermal titration calorimetry (ITC), dynamic light scattering (DLS), and circular dichroism (CD) to assess DMCA's effect on PrP.
- Molecular docking to predict DMCA binding sites on PrP.
- Cell viability assays using SH-SY5Y cells treated with prion oligomers and DMCA.
Main Results:
- DMCA binds potently to prion protein (Kd = 405 nM).
- DMCA reduces PrP oligomer formation by 30-40% and enhances cell viability.
- Molecular docking suggests DMCA stabilizes PrP tertiary structure.
Conclusions:
- DMCA is a bioavailable coffee component with significant anti-prion properties.
- DMCA demonstrates potential for the prophylaxis of neurodegenerative diseases.
- Further research into DMCA for neurodegenerative disease prevention is warranted.
